Durability of Sirolimus for Lymphangioleiomyomatosis

Alexandra Martirossian, Shiwan Shah, Lola Carrete, Jose Valle, Vincent Valentine

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lymphangioleiomyomatosis (LAM), a rare, multisystem disorder primarily affecting women of reproductive age, is characterized by cystic-appearing lung lesions, progressive loss of lung function, chylous effusions and renal angiomyolipomas. Sirolimus, an mammalian target of rapamycin inhibitor, has been shown to stabilize lung function, reduce symptoms and resolve chylous effusions in the short term for patients with LAM. Herein, we report a premenopausal female with LAM who experienced complete and durable resolution of her chylothoraces with significant and sustained improvement in lung function on sirolimus.

Original languageEnglish (US)
Pages (from-to)603-607
Number of pages5
JournalThe American journal of the medical sciences
Volume354
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Lymphangioleiomyomatosis
Sirolimus
Lung
Chylothorax
Angiomyolipoma
Kidney

Keywords

  • Chylothorax
  • Lymphangioleiomyomatosis
  • Sirolimus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Durability of Sirolimus for Lymphangioleiomyomatosis. / Martirossian, Alexandra; Shah, Shiwan; Carrete, Lola; Valle, Jose; Valentine, Vincent.

In: The American journal of the medical sciences, Vol. 354, No. 6, 01.12.2017, p. 603-607.

Research output: Contribution to journalArticle

Martirossian, Alexandra ; Shah, Shiwan ; Carrete, Lola ; Valle, Jose ; Valentine, Vincent. / Durability of Sirolimus for Lymphangioleiomyomatosis. In: The American journal of the medical sciences. 2017 ; Vol. 354, No. 6. pp. 603-607.
@article{58d8d7b9c0e84a8c818d4716bf21b380,
title = "Durability of Sirolimus for Lymphangioleiomyomatosis",
abstract = "Lymphangioleiomyomatosis (LAM), a rare, multisystem disorder primarily affecting women of reproductive age, is characterized by cystic-appearing lung lesions, progressive loss of lung function, chylous effusions and renal angiomyolipomas. Sirolimus, an mammalian target of rapamycin inhibitor, has been shown to stabilize lung function, reduce symptoms and resolve chylous effusions in the short term for patients with LAM. Herein, we report a premenopausal female with LAM who experienced complete and durable resolution of her chylothoraces with significant and sustained improvement in lung function on sirolimus.",
keywords = "Chylothorax, Lymphangioleiomyomatosis, Sirolimus",
author = "Alexandra Martirossian and Shiwan Shah and Lola Carrete and Jose Valle and Vincent Valentine",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.amjms.2016.11.028",
language = "English (US)",
volume = "354",
pages = "603--607",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Durability of Sirolimus for Lymphangioleiomyomatosis

AU - Martirossian, Alexandra

AU - Shah, Shiwan

AU - Carrete, Lola

AU - Valle, Jose

AU - Valentine, Vincent

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Lymphangioleiomyomatosis (LAM), a rare, multisystem disorder primarily affecting women of reproductive age, is characterized by cystic-appearing lung lesions, progressive loss of lung function, chylous effusions and renal angiomyolipomas. Sirolimus, an mammalian target of rapamycin inhibitor, has been shown to stabilize lung function, reduce symptoms and resolve chylous effusions in the short term for patients with LAM. Herein, we report a premenopausal female with LAM who experienced complete and durable resolution of her chylothoraces with significant and sustained improvement in lung function on sirolimus.

AB - Lymphangioleiomyomatosis (LAM), a rare, multisystem disorder primarily affecting women of reproductive age, is characterized by cystic-appearing lung lesions, progressive loss of lung function, chylous effusions and renal angiomyolipomas. Sirolimus, an mammalian target of rapamycin inhibitor, has been shown to stabilize lung function, reduce symptoms and resolve chylous effusions in the short term for patients with LAM. Herein, we report a premenopausal female with LAM who experienced complete and durable resolution of her chylothoraces with significant and sustained improvement in lung function on sirolimus.

KW - Chylothorax

KW - Lymphangioleiomyomatosis

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=85038129637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038129637&partnerID=8YFLogxK

U2 - 10.1016/j.amjms.2016.11.028

DO - 10.1016/j.amjms.2016.11.028

M3 - Article

VL - 354

SP - 603

EP - 607

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 6

ER -